Evidence map›Paper›PMID 42557473›Full record

ArticleJournal of molecular neuroscience : MN2026

Dopamine Receptor D2 gene Polymorphisms rs2005313, rs4274224, and rs4938019 in Pakistani Patients with Schizophrenia:a Diagnostic Tool for Schizophrenia.

Ishrat Yaseen, Saleem Ahmad, Muhammad Ghalib, Muhammad Shahbaz Aslam, Rabbia Tariq, Osheen Sajjad, Faisal Yaseen

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ishrat Yaseen *School of Medical Sciences, Johar Institute of Professional Studies, Lahore, Pakistan.ORCID http://orcid.org/0009-0006-2253-5235
Saleem Ahmad *School of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan. saleemchhimmee@gmail.com.ORCID http://orcid.org/0009-0000-1148-0087
Muhammad GhalibSchool of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan.
Muhammad Shahbaz AslamSchool of Biochemistry and Biotechnology, University of the Punjab, Lahore, Pakistan.
Rabbia TariqSchool of Medical Sciences, Johar Institute of Professional Studies, Lahore, Pakistan.
Osheen SajjadSchool of Biomedical and Allied Health Sciences, University of the Health Sciences, Lahore, Pakistan.
Faisal YaseenSchool of Biomedical and Allied Health Sciences, University of the Health Sciences, Lahore, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study was designed to evaluate the genetic association of three specific intronic Single Nucleotide Polymorphisms (SNPs) within the Dopamine Receptor D2 (DRD2) gene-rs2005313, rs4274224, and rs4938019-with schizophrenia susceptibility in a Pakistani population. The primary objective was to identify population-specific biomarkers that could inform early intervention and personalized treatment strategies.

methodsGenotyping was conducted on a matched case-control cohort of 208 participants (104 cases; 104 controls) using High-Resolution Melting (HRM) PCR. Genetic associations were quantified using Odds Ratios (OR) and 95% Confidence Intervals (CI), representing the standard coefficient and its margin of error to ensure statistical precision. Functional annotation of the investigated polymorphisms was performed using GTEx, FORGEdb and RegulomeDB to assess regulatory potential and tissue-specific expression effects.

resultsThe research identified highly significant associations across multiple inheritance models, validating the technical robustness of the findings. The rs4938019 polymorphism emerged as the most potent genetic risk factor, particularly under the recessive model (OR: 9.60; 95% CI: 3.92-23.52; p < 0.0001), where the rare GG genotype was found in 44% of cases compared to only 7.2% of controls. Conversely, rs4274224 demonstrated a significant protective effect, with a co-dominant OR of 0.23 (95% CI: 0.09-0.59; p = 0.0022), suggesting that the T allele confers genetic resilience. Furthermore, among the investigated DRD2 variants, rs2005313 demonstrated significance primarily under the over-dominant inheritance model, whereas rs4938019 exhibited the strongest association under the recessive model (OR: 2.13; 95% CI: 1.15-3.94; p = 0.014). All variants in the control group maintained Hardy-Weinberg Equilibrium (p > 0.05), confirming the absence of population bias. Functional annotation revealed that rs4274224 showed the strongest direct regulatory evidence for DRD2 (FORGEdb score: 6; RegulomeDB Rank 1f), while rs4938019 demonstrated the highest overall regulatory potential (FORGEdb score: 9), with rs2005313 exhibiting substantial regulatory evidence (FORGEdb score: 7) supported by extensive GTEx cis-eQTLs across multiple tissues including brain regions.

conclusionThese findings establish DRD2 intronic polymorphisms as critical determinants of schizophrenia risk. The high-risk rs4938019 GG genotype provides a clear translational biomarker for rapid genetic screening, potentially improving clinical outcomes through genotype-guided therapeutic interventions.

Indexed as

Polymorphism, Single NucleotideReceptors, Dopamine D2SchizophreniaAdultCase-Control StudiesFemaleGenetic Predisposition to DiseaseHumansMaleMiddle AgedPakistanDRD2 protein, humanReceptors, Dopamine D2dopamine receptor D2 (DRD2) genepsychiatric disorderSchizophreniasingle nucleotide polymorphisms

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.